Long-term Effects of Peptide Use in Bodybuilding

The Known Devil vs. The New Equation

When we talk about the long-term risks of anabolic steroids, it's a well-trod path. Decades of use in bodybuilding and medicine have given us a clear, if ugly, picture of what chronic steroid use does. Lipids get worse and the heart works harder. Oral compounds can damage the liver, and the body's own testosterone production shuts down. It's the devil we know. SARMs are the newer cousins, and while the data is thinner, we're seeing similar patterns of lipid disruption and testosterone suppression.

Peptides are a different case. Their long-term risks don't come from hammering the androgen receptor. They come from manipulating the body's own signaling systems, which can be done gently or not. A rough analogy: steroids swap out the car's engine, while growth hormone peptides reprogram the factory engine to run harder for longer. Things can still go wrong, but the points of failure are in different places. For a broader side-by-side, see our page on how long-term risks compare between peptides and other performance drugs.

GHS Peptides: The Insulin and Cancer Questions

For bodybuilders, the most popular peptides are the growth hormone secretagogues (GHS), such as CJC-1295 paired with Ipamorelin, or one of the GHRPs. They prompt the pituitary to release more of the body's own growth hormone. That's a different mechanism from injecting synthetic HGH at supraphysiological doses, and lifters generally see it as 'gentler'. But 'gentler' isn't the same as 'harmless', especially over the long haul.

The first major long-term concern is insulin resistance. Chronically elevated GH and its downstream partner, IGF-1, oppose insulin. GH works against insulin's effects at the cellular level, so the pancreas has to release more insulin to keep blood sugar in check. Over months or years, that can mean lower insulin sensitivity and, in some people, pre-diabetes. The clearest human picture comes from acromegaly (pathologically high GH), where clinical reviews list glucose disorders and diabetes among the complications, though reported rates vary between studies.

For a secretagogue specifically, the best data come from a 2-year randomized trial of the oral GH secretagogue MK-677 in 65 healthy adults aged 60-81. Participants received 25 mg daily. In the MK-677 group, fasting glucose rose by an average of about 5 mg/dL and insulin sensitivity fell. That's one compound in older adults, and nobody has run a comparable long-term trial of CJC-1295 or ipamorelin in young lifters. The direction of the effect matches what GH does in general, which is why year-round use draws the most concern.

The second, more controversial question is cancer. IGF-1 is a strong growth signal, and it doesn't act only on muscle cells. The concern is that chronically raised IGF-1 could speed the growth of cancer cells that are already present but undiagnosed. Observational studies have linked high-normal or elevated IGF-1 levels to a higher risk of some cancers. Prostate and breast cancer are among the most studied. A 2007 overview in Endocrine Reviews also describes conflicting evidence on how much IGF signaling matters in human cancer. No study has shown that a CJC-1295 and ipamorelin course causes cancer, and none has followed users long enough to look. What we do know is that these compounds raise a hormone tied closely to cancer cell growth. That's a reason for caution with long-term use, not proof of harm.

The Healing Peptides: Unchecked Growth Signals?

Then we have the recovery compounds like BPC-157 and TB-500, which lifters use for tendonitis and muscle strains. In animal studies, BPC-157 promotes angiogenesis (the growth of new blood vessels) along with upregulation of vascular endothelial growth factor (VEGF). More blood vessels at an injured site means a better supply of nutrients for repair, which is the usual explanation for the faster tendon and muscle healing seen in rodents.

What happens over a year of use is unknown. A 2025 systematic review found 36 relevant studies, 35 of them preclinical. Animal safety studies lasting up to 6 weeks showed no organ damage, but the authors found no clinical safety data. As of October 2026, only three small uncontrolled human pilots have been published, and none reported adverse effects. There are no long-term human data for either compound.

The open question mirrors the IGF-1 one, just on a different axis. Angiogenesis is also how tumors secure a blood supply, so a compound that promotes it raises a theoretical concern with long-term use. The preclinical evidence points both ways: a 2025 narrative review notes that BPC-157 inhibited cell growth and VEGF signaling in a human melanoma cell line, the opposite of what a tumor promoter would do. That's cell-culture data, not a human safety finding. Users mostly describe BPC-157 as something they use for a specific injury over a limited stretch rather than continuously, and the missing long-term data is a fair argument for that pattern.

A Table of Risks: How They Really Stack Up

The risks aren't simply better or worse. They're different, and they rest on very different amounts of evidence. Calling peptides 'side-effect free' ignores both points. Our page on how peptides and steroids differ in mechanism and results covers the short-term side.

Read across the rows and the trade-off shows. With steroids, the main cost is cardiovascular and endocrine health. GHS peptides swap much of that androgenic risk for a metabolic one, while the healing peptides carry mostly unknowns because nobody has measured long-term use in people.

Short Courses vs. Year-Round Use

A common criticism in lifting communities is that people bring a steroid mentality to peptides. The "blast and cruise" model of continuous use is a poor fit for compounds whose main known risk builds with exposure time.

Year-round GHS use means chronically higher GH and IGF-1, and the MK-677 trial's 2-year analysis confirmed its 1-year findings, including the glucose changes. Many users instead describe GHS courses of 8-12 weeks, sometimes timed to a contest prep, followed by a break at least as long. That pattern comes from community practice rather than a trial. We found no study testing whether time off restores insulin sensitivity. Our page on peptide cycling protocols covers the schedules users report. For BPC-157, users typically describe a course aimed at one injury that ends once the injury settles.

The long-term effects of peptide use are less visible than the side effects of a heavy testosterone and trenbolone cycle. There's no acne and no shutdown in the short term. The risks are slower and mostly metabolic, the result of pushing growth pathways harder and for longer than the body normally does. That doesn't make them smaller than steroid risks, only harder to notice early.

What we still don't know

• Whether GHS-related drops in insulin sensitivity reverse fully after stopping, and how long that takes in younger, leaner users than the MK-677 trial studied.
• Whether years of raised IGF-1 from secretagogue use changes cancer risk. No study has followed users long enough to tell.
• Whether BPC-157's effect on blood vessel growth matters outside an injury. The animal safety work stops at about 6 weeks, and the human pilots were small and uncontrolled.